NEUROENDOCRINE CARCINOMA
Clinical trials for NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill takes on tough cancers in first human trial
Disease control Recruiting nowThis early-stage study tests an experimental pill called CID-078 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 220 adults with cancers like lung, breast…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Circle Pharma • Aim: Disease control
Last updated May 26, 2026 12:12 UTC
-
New drug combo aims to shrink Hard-to-Treat lung tumors
Disease control Recruiting nowThis study tests whether combining two experimental drugs (ZG006 and ZG005) can shrink tumors in people with advanced small cell lung cancer or neuroendocrine carcinoma. About 350 adults aged 18-70 will receive the combination to check safety and effectiveness. The goal is to see…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
Virus plus immunotherapy combo targets hard-to-treat neuroendocrine cancers
Disease control Recruiting nowThis early-phase trial tests a virus that attacks cancer cells (SVV-001) together with two immunotherapy drugs (nivolumab and ipilimumab) in adults with advanced neuroendocrine tumors or carcinomas that have worsened after standard treatment. The main goals are to find the safest…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
New chemo combo tested for rare, aggressive gut cancer
Disease control Recruiting nowThis study tests whether a chemotherapy regimen called FOLFIRINOX works better than the standard platinum-etoposide combination for people with advanced, fast-growing neuroendocrine cancer of the digestive system or unknown origin. About 218 participants will receive one of the t…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated May 26, 2026 12:00 UTC
-
New hope for tough cancers: ZG006 trial opens for patients out of options
Disease control Recruiting nowThis study tests a new drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or can't tolerate them. The goal is to find a safe dose and see if the drug can shrink tumors. About 54 adults aged 18 to 75 will tak…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for rare cancer: tarlatamab takes on chemo in phase 3 trial
Disease control Recruiting nowThis Phase 3 trial compares the experimental drug tarlatamab to standard chemotherapy in 129 adults with advanced neuroendocrine carcinoma (a rare cancer of the lung or digestive system) that has worsened after prior treatment. The main goal is to see if tarlatamab helps people l…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Gene-Guided drug dosing could improve neuroendocrine cancer treatment
Disease control Recruiting nowThis study aims to see if adjusting the dose of the drug belinostat based on a person's genetic makeup can make treatment safer and more effective for high-grade neuroendocrine carcinomas. About 60 adults with this type of cancer will receive belinostat along with two other chemo…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:04 UTC
-
Immunotherapy shows promise for rare cancers in new trial
Disease control Recruiting nowThis study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy as the first treatment for people with advanced cancers that have specific genetic markers (dMMR/MSI). The cancers studied are rare types like pancreatic, stomach, and small bowel …
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Lung cancer patients screened for genetic clues to future treatments
Knowledge-focused Recruiting nowThis study screens up to 797 people with relapsed small cell lung cancer to identify genetic changes in their tumors. No experimental drugs are given; instead, researchers analyze tissue and blood samples to classify cancer subtypes. The goal is to prepare for future trials that …
Matched conditions: NEUROENDOCRINE CARCINOMA
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated May 26, 2026 12:00 UTC